Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CMV complications in common variable immunodeficiency.

T Witte1, S Werwitzke, R E Schmidt

  • 1Abteilung Klinische Immunologie, Medizinische Hochschule Hannover, Germany. witte.torsten@mh.hannover.de

Immunobiology
|September 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe acute neurotoxicity reflects absolute intra-carotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine dose in non-human primates.

Journal of neuroscience methods·2021
Same author

[Health services research in rheumatology : Identifying gaps in health care and filling them through innovative concepts].

Zeitschrift fur Rheumatologie·2019
Same author

[Experiences and results from Rheuma-VOR].

Zeitschrift fur Rheumatologie·2019
Same author

[Early recognition and screening consultation: a necessary way to improve early detection and treatment in rheumatology? : Overview of the early recognition and screening consultation models for rheumatic and musculoskeletal diseases in Germany].

Zeitschrift fur Rheumatologie·2019
Same author

Zidovudine-Mediated Autophagy Inhibition Enhances Mitochondrial Toxicity in Muscle Cells.

Antimicrobial agents and chemotherapy·2018
Same author

[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

Zeitschrift fur Rheumatologie·2017

A patient with common variable immunodeficiency developed myelitis during glucocorticosteroid treatment. A subsequent cytomegalovirus infection, unusual for this condition, was linked to an NK cell defect and immunosuppressive therapy.

Area of Science:

  • Immunology
  • Neurology
  • Infectious Diseases

Background:

  • Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by impaired antibody production.
  • Patients with CVID are susceptible to infections, but specific opportunistic infections can be atypical.
  • Treatment with immunosuppressive medications can further increase infection risk.

Purpose of the Study:

  • To describe a case of myelitis and subsequent cytomegalovirus (CMV) infection in a patient with CVID.
  • To investigate the immunological factors contributing to atypical infections in CVID patients undergoing immunosuppressive therapy.
  • To highlight the diagnostic challenges and management of complex complications in CVID.

Main Methods:

  • Case report detailing clinical presentation, treatment, and diagnostic workup.

Related Experiment Videos

  • Immunological assessment including functional Natural Killer (NK) cell activity.
  • Review of literature regarding CVID complications and CMV infections.

    • Main Results:

    • A CVID patient developed myelitis during glucocorticosteroid treatment.
    • The patient later experienced exacerbation of neurological and other inflammatory symptoms, diagnosed as CMV infection.
    • A functional NK cell defect was identified, potentially predisposing the patient to CMV infection alongside immunosuppressive therapy.

    Conclusions:

    • Cytomegalovirus infection is an atypical but possible complication in CVID patients, especially under immunosuppressive treatment.
    • Functional NK cell defects may play a role in susceptibility to certain infections in CVID.
    • This case underscores the importance of considering opportunistic infections and underlying immune defects in CVID management.